31321014|t|Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus.
31321014|a|Elderly patients with diabetes are at high risk of polypharmacy because of multiple coexisting diseases and syndromes. Polypharmacy increases the risk of drug-drug and drug-disease interactions in these patients, who may already have age-related sensory and cognitive deficits; such deficits may delay timely communication of early symptoms of adverse drug events. Several glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been approved for diabetes: liraglutide, exenatide, lixisenatide, dulagluatide, semaglutide, and albiglutide. Some are also approved for treatment of obesity. The current review of literature along with clinical case discussion provides evidence supporting GLP-1 RAs as diabetes medications for polypharmacy reduction in older diabetes patients because of their multiple pleiotropic effects on comorbidities (e.g. hyperlipidemia, hypertension, and fatty liver) and syndromes (e.g. osteoporosis and sleep apnea) that commonly co-occur with diabetes. Using one medication (in this case, GLP-1 RAs) to address multiple conditions may help reduce costs, medication burden, adverse drug events, and medication nonadherence.
31321014	11	43	glucagon-like peptide 1 receptor	Gene	2740
31321014	79	87	patients	Species	9606
31321014	93	110	diabetes mellitus	Disease	MESH:D003920
31321014	120	128	patients	Species	9606
31321014	134	142	diabetes	Disease	MESH:D003920
31321014	315	323	patients	Species	9606
31321014	358	388	sensory and cognitive deficits	Disease	MESH:D003072
31321014	485	517	glucagon-like peptide-1 receptor	Gene	2740
31321014	528	533	GLP-1	Gene	2740
31321014	534	537	RAs	Chemical	MESH:D011883
31321014	562	570	diabetes	Disease	MESH:D003920
31321014	585	594	exenatide	Chemical	MESH:D000077270
31321014	596	608	lixisenatide	Chemical	MESH:C479460
31321014	610	622	dulagluatide	Chemical	-
31321014	694	701	obesity	Disease	MESH:D009765
31321014	801	806	GLP-1	Gene	2740
31321014	807	810	RAs	Chemical	MESH:D011883
31321014	814	822	diabetes	Disease	MESH:D003920
31321014	871	879	diabetes	Disease	MESH:D003920
31321014	880	888	patients	Species	9606
31321014	958	972	hyperlipidemia	Disease	MESH:D006949
31321014	974	986	hypertension	Disease	MESH:D006973
31321014	992	1003	fatty liver	Disease	MESH:D005234
31321014	1025	1037	osteoporosis	Disease	MESH:D010024
31321014	1042	1053	sleep apnea	Disease	MESH:D012891
31321014	1083	1091	diabetes	Disease	MESH:D003920
31321014	1129	1134	GLP-1	Gene	2740
31321014	1135	1138	RAs	Chemical	MESH:D011883
31321014	Negative_Correlation	MESH:D009765	2740
31321014	Positive_Correlation	MESH:D011883	MESH:D012891
31321014	Positive_Correlation	MESH:D005234	2740
31321014	Negative_Correlation	MESH:C479460	MESH:D003920
31321014	Negative_Correlation	MESH:D006949	2740
31321014	Negative_Correlation	MESH:D006973	2740
31321014	Negative_Correlation	MESH:D011883	MESH:D009765
31321014	Positive_Correlation	MESH:D010024	2740
31321014	Positive_Correlation	MESH:D000077270	2740
31321014	Positive_Correlation	MESH:C479460	2740
31321014	Negative_Correlation	MESH:D000077270	MESH:D009765
31321014	Negative_Correlation	MESH:D011883	MESH:D006973
31321014	Positive_Correlation	MESH:D011883	MESH:D005234
31321014	Negative_Correlation	MESH:D003920	2740
31321014	Negative_Correlation	MESH:D011883	MESH:D003920
31321014	Negative_Correlation	MESH:D000077270	MESH:D003920
31321014	Negative_Correlation	MESH:D011883	MESH:D010024
31321014	Negative_Correlation	MESH:D011883	MESH:D006949
31321014	Positive_Correlation	MESH:D012891	2740

